Supplementary Materials

Supplementary Material for:

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses

Marij J. Welters, Tetje C. van der Sluis, Hélène van Meir, Nikki M. Loof, Vanessa J. van Ham, Suzanne van Duikeren, Saskia J. Santegoets, Ramon Arens, Marieke L. de Kam, Adam F. Cohen, Mariette I. van Poelgeest, Gemma G. Kenter, Judith R. Kroep, Jacobus Burggraaf, Cornelis J. Melief, Sjoerd H. van der Burg*

*Corresponding author. E-mail: shvdburg{at}lumc.nl

Published 13 April 2016, Sci. Transl. Med. 8, 334ra52 (2016)
DOI: 10.1126/scitranslmed.aad8307

This PDF file includes:

  • Materials and Methods
  • Fig. S1. T cells are not affected by CarboTaxol treatment.
  • Fig. S2. The delay in tumor growth does not differ between the treatment groups.
  • Fig. S3. Chemotherapy does not hamper T cells but decreases myeloid cell frequencies.
  • Fig. S4. The combination of carboplatin and paclitaxel results in the strongest reduction of circulating myeloid cells.
  • Fig. S5. CarboTaxol therapy does not influence general immune parameters.
  • Fig. S6. CarboTaxol therapy alters the relative frequencies of myeloid cells and lymphocytes.
  • Fig. S7. Myeloid cells and T cells in blood samples from cervical cancer patients were analyzed by flow cytometry.
  • Fig. S8. CarboTaxol treatment affects different subpopulations of CD11b+ and/or CD14+ myeloid cells.
  • Fig. S9. CarboTaxol therapy reduces the number of regulatory T cells in cervical cancer patients.
  • Fig. S10. HPV16-SLP vaccination induces polyfunctional T cells.
  • Fig. S11. The vaccine-induced HPV16-specific T cell response is stronger in patients vaccinated during chemotherapy.
  • Fig. S12. Myeloid cell depletion improves the response of PBMC to stimulation in vitro.
  • Table S1. Patient characteristics.
  • Table S2. AEs systemically and at vaccination site.
  • Reference (35)

[Download PDF]